ArticleMaterials today. Bio2025
Construction and characteristics of an adjustable biomechanical in vitro corneal stromal model simulating keratoconus pathological features.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microengineered Gradient Hydrogels for Mechanobiology.Advanced healthcare materials · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus (KC) is a prevalent ectatic corneal disease influenced by corneal biomechanics, though its pathogenesis remains unclear. Constructing an in vitro corneal model with adjustable biomechanics is essential for studying keratoconus. In this study, a KC disease group (L group) was created using a low matrix stiffness collagen hydrogel containing human corneal stromal cells (hCSCs), while a high matrix stiffness group (H group) was established using a plastic compression method. Additionally, a cross-linking treatment model was applied to the L group using corneal collagen cross-linking (CXL). Results showed that the matrix stiffness of the L group was significantly lower compared to the H group. Both the L group and clinical KC samples exhibited lower collagen fibrils density. Transcriptomic and proteomic analyses revealed decreased antioxidant capacity and increased levels of inflammatory factors and reactive oxygen species (ROS) in the L group. The NRF2 pathway activity was downregulated. In the L group cells, inflammation-related genes were upregulated, antioxidant-related genes were downregulated, and ROS levels were elevated, accompanied by a reduction in mitochondrial membrane potential. The concentrations of IL-6 and TNF-α in the culture medium were increased. Histological results indicated that the L group, similar to clinical KC samples, exhibited high expression of inflammatory and oxidative stress factors, while signals of antioxidant-related factors were decreased. After cross-linking treatment, the L group demonstrated increased matrix stiffness, higher collagen fibrils density, upregulated expression of antioxidant factors, and decreased expression of inflammatory and immune factors. This study successfully established an in vitro corneal stromal model with adjustable matrix stiffness, providing a platform for investigating the pathogenesis of KC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.